Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage

Inclusion criteria

• Age ≥ 18 years, regardless of gender;
• Supratentorial ICH confirmed by brain CT scan;
• No disability in the community before ICH (premorbid mRS≤1);
• Neurological deficits related to the hematoma, with NIHSS score ≥ 6 and single-limb motor item score ≥ 2;
• GCS score ≥ 6;
• Able to initiate the first dose of minocycline within 24 hours of onset;
• Signed and dated informed consent.

Exclusion criteria

• Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs;
• Allergy to tetracycline antibiotics;
• Use of vitamin A derivatives or steroid therapy within the past 3 months;
• Concomitant infection requiring antibiotic treatment at admission;
• Planned surgical intervention;
• Life expectancy of less than 6 months due to comorbid conditions;
• Severe hepatic and renal dysfunction, or AST and/or ALT >3 times the upper limit of reference range, or serum creatinine >265 μmol/L (> 3 mg/dL);
• Bleeding tendency, including heparin use within the past 48 hours (APTT ≥ 35 s), oral warfarin (INR > 2), platelet count < 100 × 10⁹/L, or hereditary hemorrhagic diseases;
• Known pregnancy or breastfeeding;
• Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;
• A high likelihood that the patient will not adhere to the study treatment and follow-up regimen;
• Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.